Cocrystal Pharma, Inc. · NASDAQ:COCP
Cocrystal Pharma — Investor Presentation (October 2022)
32 slides from Cocrystal Pharma's investor presentation, Oct 26, 2022
Slide 1: Potent antivirals to combat some of the most serious diseases facing humanity
Slide 2: Forward-Looking Statement
Forward-Looking Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the market opportunities for the treatment of acute and chronic viral diseases which are the focus of our program
Slide 3: About Cocrystal Pharma
About Cocrystal Pharma Advancing programs in high-value antiviral drug targets » Pandemic SARS-CoV-2, SARS-CoV-2 variants, and coronaviruses « Pandemic and seasonal influenza A ¢ Norovirus gastroenteritis Applying powerful, proprietary : Drug candidates with clinically validated mechanisms of action
Slide 4: Investment Highlights
Investment Highlights e Targeting large, global markets for the treatment of acute and pandemic viral diseases e Proprietary drug discovery platform technology e Advancing COVID-19 and influenza programs e COVID-19 CDI-988 oral protease inhibitor — Planned Phase 1 trial initiation in Q1 2023 e COVID
Slide 5: Pipeline
COVID-19 COVID-19 (Licensed) COVID-19 Influenza A Influenza A/B Hepatitis C (HCV) Norovirus Gastroenteritis Oral Protease Inhibitors CDI-45205 Protease Inhibitor Replication Inhibitors CC-42344 PB2 Inhibitor Influenza A/B Inhibitor CC-31244 Pan-genotypic NS5B NNI Replication and Protease Inhibitors
Slide 6: Platform Provides Rapid, Efficient Drug Discovery and Development
Platform Provides Rapid, Efficient Drug Discovery and Development Traditional antiviral drug discovery and development can be long, costly and risky, with high rates of attrition Cocrystal’s technology platform provides potential for viable drug candidates at reduced costs and with shorter discovery
Slide 7: Proprietary Drug Discovery Platform Technology for Direct-Acting-Antivirals
Proprietary Drug Discovery Platform Technology for Direct-Acting-Antivirals Cocrystal’s technology platform provides potential for novel drug candidates at reduced development timelines and costs Grow drug target Select Drug Hit-to-lead Lead = 7 soe x-ray crystals binding pocket process optimization
Slide 8: Robust Antiviral Drug Discovery Founded by Proprietary Technology
Robust Antiviral Drug Discovery Founded by Proprietary Technology e Provide 3D structures of inhibitor protein complexes at near-atomic resolution with immediate insight to guide chemistry e Identify novel drug binding pockets e Design and develop broad-spectrum inhibitors with high barrier to drug
Slide 9: SARS-CoV-2 and SARS-CoV-2 Variants, and other Coronaviruses
SARS-CoV-2 and SARS-CoV-2 Variants, and other Coronaviruses
Slide 10: Significant Need for Antivirals to Combat Coronavirus Infections
Significant Need for Antivirals to Combat Coronavirus Infections e There is no approved COVID-19 antiviral prophylactic treatment e Merck's molnupiravir and Pfizer's paxlovid (nimatrevir plus ritonavir) received FDA emergency use authorization e Coronaviruses constantly change through mutation’ e Mu
Slide 11: Novel COVID-19 Preclinical Leads
Novel COVID-19 Preclinical Leads SARS-CoV-2 main protease (1.8 A) SARS-CoV-1 main protease (1.56 A) MERS-CoV main protease (1.9 A) e Binds to a highly conserved, essential residue (Cys145) of SARS-CoV-2 main (3CL) protease and other coronavirus main (3CL) proteases e Exhibits broad-spectrum activity
Slide 12: COVID-19: How Cocrystal Protease Inhibitor Will Work
COVID-19: How Cocrystal Protease Inhibitor Will Work SARS -CoV-2 Infected cell Membrane usion) Replication inhibitor eSsemDy Endocytosis Release Uncoating Non-structural Structural RNA Polyproteins proteins RNA proteins Translation Proteolysis Replication Translation Main (3CL) protease inhibitor 12
Slide 13: COVID-19 Program Status
COVID-19 Program Status e Oral broad-spectrum protease inhibitor e CDI-988 selected as preclinical lead e Initiated scale-up synthesis e Planned clinical trial initiation in Q1 2023 e Oral broad-spectrum replication inhibitors e Lead discovery ongoing e Intranasal/pulmonary broad-spectrum protease i
Slide 14: Clinical Trial Design for COVID-19 Protease Inhibitors
Clinical Trial Design for COVID-19 Protease Inhibitors e Planned Phase 1 trial design for oral CDI-988 and intranasal/pulmonary CDI-45205 SARS-CoV-2 inhibitors » Randomized, placebo-controlled, double-blind, single-ascending-dose/multiple-ascending-dose trial » Healthy volunteers » Evaluate safety,
Slide 15: Influenza A Program
Influenza A Program
Slide 16: Influenza: A Major Global Health Concern
Influenza: A Major Global Health Concern * 1 billion cases’, 3-5 million severe illnesses? and up to 650,000 deaths’ worldwide annually ® Global influenza therapeutics market size is projected to reach $9.5 billion by 2027, from $6.6 billion in 2020, growing at a 4.8% CAGR between 2021 and 2027? * N
Slide 17: Cap Binding (PB2), Endonuclease (PA), and Polymerase (PB1) are Essential for Influenza Viral Replication
Cap Binding (PB2), Endonuclease (PA), and Polymerase (PB1) are Essential for Influenza Viral Replication Trimeric RNA Polymerase Com plex Nucleus Cytoplasm PBI y | \ Viral RNA elF4E Translation Host pre-mRNA | Nao nee Chimeric RNA -~ J o ¢ , OOo . rm > So AAA “Cap snatching” On, AAA Ribosome complex
Slide 18: CC-43244: Pandemic and Seasonal Influenza A Oral Therapeutic
CC-43244: Pandemic and Seasonal Influenza A Oral Therapeutic ~ . * PB2 inhibitor binds to highly conserved pocket on replication enzyme Pandemic and seasonal influenza A PB2 crystals * Exhibits excellent broad-spectrum activity against pandemic and seasonal strains, and activity against known resist
Slide 19: Influenza A/B Program with Merck
Influenza A/B Program with € MERCK
Slide 20: Collaboration Validates Technology with Potential for Lucrative Returns
Collaboration Validates Technology with Potential for Lucrative Returns * Broad-spectrum, potent candidates developed to be active against seasonal, pandemic and existing drug-resistant influenza A and B strains * Announced exclusive worldwide license and collaboration with Merck in January 2019 Coc
Slide 21: Norovirus Gastroenteritis Program
Norovirus Gastroenteritis Program
Slide 22: Norovirus: Large Market with No Approved Treatments
Norovirus: Large Market with No Approved Treatments * Highly contagious virus that causes symptoms of acute gastroenteritis including nausea, vomiting, stomach pain and diarrhea * Major cause of gastrointestinal illness in closed and crowded environments including hospitals, nursing homes, childcare
Slide 23: Developing Broad-Spectrum Norovirus Protease and Replication Inhibitors
Developing Broad-Spectrum Norovirus Protease and Replication Inhibitors * Broad-spectrum norovirus protease and replication inhibitors are being developed * Ongoing drug discovery efforts * Oral protease inhibitor discovery using its proprietary drug discovery platform technology * Preclinical evalu
Slide 24: Hepatitis C Program
Hepatitis C Program
Slide 25: Hepatitis C: Increase in Rate of New Infections
Hepatitis C: Increase in Rate of New Infections An estimated 58 million people worldwide have chronic hepatitis C virus infection, with about 1.5 million new infections occurring per year" An estimated 290,000 deaths occurred in 2019 worldwide due to hepatitis C, mostly from cirrhosis and hepatocell
Slide 26: CC-31244: HCV NNI Next-Generation Combination Cocktail Therapy
CC-31244: HCV NNI Next-Generation Combination Cocktail Therapy * Potential best-in-class HCV non-nucleoside inhibitor (NNI) with a strong profile * Broad-spectrum, potent NS5B polymerase inhibitor with high barrier to resistance ° Effective against known NNI drug-resistant variants * Once-a-day oral
Slide 27: Seasoned Leadership
Seasoned Leadership Sam Lee, Ph.D. Interim Co-Chief Executive Officer & Roger Kornberg, Ph.D. + Professor a” President we Chairman of the Board, Chairman of the Stanford University School of Medicine Icos je ic js . 25+ years of anti-infective drug Scientific Advisory Board Nobel Laureate discovery
Slide 28: Expanding Intellectual Property Portfolio
Expanding Intellectual Property Portfolio Coronavirus Norovirus * Issued patents in U.S. and major countries * Issued patents in U.S. and major countries * Pending U.S. provisional applications * Pending U.S. provisional applications Pandemic Influenza A HCV * PB2 (influenza A inhibitor) NSSB (NNI)
Slide 29: Financial Snapshot
Financial Snapshot ~$20 Million 27,000 Average 3 month Heme Ges daily share volume’ 8.2 Million Fully diluted shares Clean balance sheet No preferred shares No debt Only 20,250 warrants Cash sufficient to fund 1 Yahoo Finance (October 18, 2022) planned operations 29
Slide 30: Summary
Summary e Targeting large, global markets for the treatment of acute and pandemic viral diseases e Proprietary drug discovery platform technology e Advancing COVID-19 and influenza programs e COVID-19 CDI-988 oral protease inhibitor — Planned Phase 1 trial initiation in Q1 2023 e COVID-19 CDI-45205
Slide 31: Appendix
Appendix
Slide 32: CC-31244: HCV NNI Next-Generation Combination Cocktail Therapy
CC-31244: HCV NNI Next-Generation Combination Cocktail Therapy » Potential best-in-class HCV non-nucleoside inhibitor (NNI) with a strong profile » Broad-spectrum, potent NS5B polymerase inhibitor » Effective against known NNI drug-resistant variants » Orally administered; liver targeting Favorable
Cocrystal Pharma — Investor Presentation (October 2022) on 6ix